379 related articles for article (PubMed ID: 9449271)
1. Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity.
Fournier B; Hooper DC
Antimicrob Agents Chemother; 1998 Jan; 42(1):121-8. PubMed ID: 9449271
[TBL] [Abstract][Full Text] [Related]
2. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.
Ng EY; Trucksis M; Hooper DC
Antimicrob Agents Chemother; 1996 Aug; 40(8):1881-8. PubMed ID: 8843298
[TBL] [Abstract][Full Text] [Related]
3. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.
Ferrero L; Cameron B; Manse B; Lagneaux D; Crouzet J; Famechon A; Blanche F
Mol Microbiol; 1994 Aug; 13(4):641-53. PubMed ID: 7997176
[TBL] [Abstract][Full Text] [Related]
4. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of quinolone resistance in Staphylococcus aureus.
Tanaka M; Wang T; Onodera Y; Uchida Y; Sato K
J Infect Chemother; 2000 Sep; 6(3):131-9. PubMed ID: 11810552
[TBL] [Abstract][Full Text] [Related]
6. Effects of mutations in GrlA of topoisomerase IV from Staphylococcus aureus on quinolone and coumarin activity.
Fournier B; Hooper DC
Antimicrob Agents Chemother; 1998 Aug; 42(8):2109-12. PubMed ID: 9687416
[TBL] [Abstract][Full Text] [Related]
7. Small-colony mutants of Staphylococcus aureus allow selection of gyrase-mediated resistance to dual-target fluoroquinolones.
Pan XS; Hamlyn PJ; Talens-Visconti R; Alovero FL; Manzo RH; Fisher LM
Antimicrob Agents Chemother; 2002 Aug; 46(8):2498-506. PubMed ID: 12121924
[TBL] [Abstract][Full Text] [Related]
8. Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus.
Yamagishi J; Kojima T; Oyamada Y; Fujimoto K; Hattori H; Nakamura S; Inoue M
Antimicrob Agents Chemother; 1996 May; 40(5):1157-63. PubMed ID: 8723458
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: novel mutations suggest novel drug-target interactions.
Ince D; Hooper DC
Antimicrob Agents Chemother; 2000 Dec; 44(12):3344-50. PubMed ID: 11083638
[TBL] [Abstract][Full Text] [Related]
10. Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus.
Ito H; Yoshida H; Bogaki-Shonai M; Niga T; Hattori H; Nakamura S
Antimicrob Agents Chemother; 1994 Sep; 38(9):2014-23. PubMed ID: 7811012
[TBL] [Abstract][Full Text] [Related]
11. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.
Pan XS; Fisher LM
J Bacteriol; 1996 Jul; 178(14):4060-9. PubMed ID: 8763932
[TBL] [Abstract][Full Text] [Related]
12. Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC.
Schmitz FJ; Jones ME; Hofmann B; Hansen B; Scheuring S; Lückefahr M; Fluit A; Verhoef J; Hadding U; Heinz HP; Köhrer K
Antimicrob Agents Chemother; 1998 May; 42(5):1249-52. PubMed ID: 9593159
[TBL] [Abstract][Full Text] [Related]
13. Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases.
Blanche F; Cameron B; Bernard FX; Maton L; Manse B; Ferrero L; Ratet N; Lecoq C; Goniot A; Bisch D; Crouzet J
Antimicrob Agents Chemother; 1996 Dec; 40(12):2714-20. PubMed ID: 9124828
[TBL] [Abstract][Full Text] [Related]
14. Quinolone resistance mutations in the GrlB protein of Staphylococcus aureus.
Tanaka M; Onodera Y; Uchida Y; Sato K
Antimicrob Agents Chemother; 1998 Nov; 42(11):3044-6. PubMed ID: 9797253
[TBL] [Abstract][Full Text] [Related]
15. Characterization of gyrA, gyrB, grlA and grlB mutations in fluoroquinolone-resistant clinical isolates of Staphylococcus aureus.
Takahashi H; Kikuchi T; Shoji S; Fujimura S; Lutfor AB; Tokue Y; Nukiwa T; Watanabe A
J Antimicrob Chemother; 1998 Jan; 41(1):49-57. PubMed ID: 9511037
[TBL] [Abstract][Full Text] [Related]
16. Detection of grlA and gyrA mutations in 344 Staphylococcus aureus strains.
Wang T; Tanaka M; Sato K
Antimicrob Agents Chemother; 1998 Feb; 42(2):236-40. PubMed ID: 9527766
[TBL] [Abstract][Full Text] [Related]
17. Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus.
Fukuda H; Hori S; Hiramatsu K
Antimicrob Agents Chemother; 1998 Aug; 42(8):1917-22. PubMed ID: 9687384
[TBL] [Abstract][Full Text] [Related]
18. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone.
Ince D; Zhang X; Silver LC; Hooper DC
Antimicrob Agents Chemother; 2002 Nov; 46(11):3370-80. PubMed ID: 12384338
[TBL] [Abstract][Full Text] [Related]
19. Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus.
Schmitz FJ; Hofmann B; Hansen B; Scheuring S; Lückefahr M; Klootwijk M; Verhoef J; Fluit A; Heinz HP; Köhrer K; Jones ME
J Antimicrob Chemother; 1998 Apr; 41(4):481-4. PubMed ID: 9598779
[TBL] [Abstract][Full Text] [Related]
20. Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae.
Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Nishino Y; Ishihara S; Kawada Y
J Antimicrob Chemother; 1997 Oct; 40(4):543-9. PubMed ID: 9372424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
